

Zydus' Neshor Pharmaceuticals receives final approval from the USFDA for Omega-3-Acid Ethyl Esters Capsules

Ahmedabad, 15 June 2019

Zydus' Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the USFDA to market Omega-3-Acid Ethyl Esters Capsules USP (US RLD – Lovaza Capsules), 1 gram. Omega-3 acid ethyl esters, a type of fat found in fish oil, is used along with diet and exercise to help lower levels of a certain blood fat (triglyceride). It may also raise good cholesterol (HDL). The drug will be manufactured at Neshor Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA.

The group now has 267 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
